Home > News > Mednax Can Sustain EPS Growth By Consolidating Nanotechnology, Morgan Keegan Reports
October 25th, 2010
Mednax Can Sustain EPS Growth By Consolidating Nanotechnology, Morgan Keegan Reports
Abstract:
Morgan Keegan said that its EPS estimate of $1.05 versus $1.03 in the prior year period is in line with the First Call consensus, adding, "We are confident that the company's earnings will at least meet Mednax's guidance of $1.03-$1.07."
Mednax closed Friday at $56.96.
Source:
benzinga.com
Bookmark:
| Related News Press |
News and information
Researchers develop molecular qubits that communicate at telecom frequencies October 3rd, 2025
Next-generation quantum communication October 3rd, 2025
"Nanoreactor" cage uses visible light for catalytic and ultra-selective cross-cycloadditions October 3rd, 2025
Announcements
Rice membrane extracts lithium from brines with greater speed, less waste October 3rd, 2025
Researchers develop molecular qubits that communicate at telecom frequencies October 3rd, 2025
Next-generation quantum communication October 3rd, 2025
"Nanoreactor" cage uses visible light for catalytic and ultra-selective cross-cycloadditions October 3rd, 2025
Financial Reports
Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Second Quarter Results April 16th, 2021
Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Second Quarter Results April 16th, 2021
 |
||
 |
||
| The latest news from around the world, FREE | ||
 |
||
|
|
||
| Premium Products | ||
 |
||
|
Only the news you want to read!
Learn More |
||
 |
||
|
Full-service, expert consulting
Learn More |
||
|
|
||